Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma

Armin Rashidi, Amanda F. Cashen

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


The prognosis of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) remains poor and current treatments are typically of limited benefit. Histone deacetylase (HDAC) inhibitors have proven effective for the treatment of relapsed/refractory PTCL. To date approved HDAC inhibitors for patients with T-cell lymphoma are vorinostat, romidepsin and, recently, belinostat. Here we review the pharmacology and the clinical activity of belinostat. Belinostat is a well-tolerated HDAC inhibitor that has shown activity in heavily pretreated patients with relapsed/refractory PTCL. Several clinical trials are currently investigating the use of belinostat in different cancers and in combination with other chemotherapeutic agents.

Original languageEnglish (US)
Pages (from-to)1659-1664
Number of pages6
JournalFuture Oncology
Issue number11
StatePublished - Jun 1 2015

Bibliographical note

Publisher Copyright:
© 2015 Future Medicine Ltd.


  • T-cell lymphoma
  • belinostat
  • histone deacetylase inhibitor


Dive into the research topics of 'Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma'. Together they form a unique fingerprint.

Cite this